Opus Genetics, Inc. (IRD) stock
IRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30483% above fair value
$4.06−0.25 (-5.80%)
Close on Nov 12, 2026Market cap $337.78MP/E –Yield –
Opus Genetics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Opus Genetics's ebitda for the twelve months ending Sep 30, 2020 was -$894.66K. For fiscal 2019 it was -$4.15M. The highest annual figure on record is -$4.15M in fiscal 2019.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | -$4.15M | – |
| FY2018 | Dec 31, 2018 | -$20.49M | – |
| FY2017 | Dec 31, 2017 | -$17.31M | – |
| FY2016 | Dec 31, 2016 | -$16.38M | – |
| FY2015 | Dec 31, 2015 | -$18.24M | – |
| FY2014 | Dec 31, 2014 | -$13.24M | – |
| FY2013 | Dec 31, 2013 | -$7.94M | – |
| FY2012 | Dec 31, 2012 | -$6.54M | – |
| FY2011 | Dec 31, 2011 | -$16.09M | – |
| FY2010 | Dec 31, 2010 | -$10.26M | – |
| FY2009 | Dec 31, 2009 | -$6.42M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2020 | Sep 30, 2020 | -$1.94M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.25M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.73M | – |
| Q4 FY2019 | Dec 31, 2019 | $5.02M | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.27M | – |
| Q2 FY2019 | Jun 30, 2019 | -$2.98M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.93M | – |
| Q4 FY2018 | Dec 31, 2018 | -$4.96M | – |
| Q3 FY2018 | Sep 30, 2018 | -$4.67M | – |
| Q2 FY2018 | Jun 30, 2018 | -$4.99M | – |
| Q1 FY2018 | Mar 31, 2018 | -$5.87M | – |
| Q4 FY2017 | Dec 31, 2017 | -$4.89M | – |
| Q3 FY2017 | Sep 30, 2017 | -$4.21M | – |
| Q2 FY2017 | Jun 30, 2017 | -$4.27M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.94M | – |
| Q4 FY2016 | Dec 31, 2016 | -$3.91M | – |
See a number that looks wrong?